Skip to main content

and
  1. No Access

    Article

    Book review

    P. Shaw in The Histochemical Journal (1990)

  2. No Access

    Article

    Terminology for sample collection in clinical genetic studies

    B B Spear, M E Heath-Chiozzi, D M Barnes, K Cheeseman in The Pharmacogenomics Journal (2001)

  3. Article

    Open Access

    Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer

    Mutations in genes for hereditary non-polyposis colorectal cancer (HNPCC) in ovarian cancer patients remains poorly defined. We sought to estimate the frequency and characteristics of HNPCC gene mutations in a...

    T Pal, M R Akbari, P Sun, J-H Lee, J Fulp, Z Thompson in British Journal of Cancer (2012)

  4. Article

    Open Access

    Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

    Folate receptor 1 (FOLR1) is expressed in the majority of ovarian carcinomas (OvCa), making it an attractive target for therapy. However, clinical trials testing anti-FOLR1 therapies in OvCa show mixed results...

    M Köbel, J Madore, S J Ramus, B A Clarke, P D P Pharoah in British Journal of Cancer (2014)

  5. Article

    Open Access

    Association study of candidate DNA-repair gene variants and acute graft versus host disease in pediatric patients receiving allogeneic hematopoietic stem-cell transplantation

    Acute Graft versus Host Disease (aGvHD) grades 2–4 occurs in 15–60% of pediatric patients undergoing allogeneic haematopoietic stem-cell transplantation (allo-HSCT). The collateral damage to normal tissue by c...

    C. R. S. Uppugunduri, P. Huezo-Diaz Curtis, T. Nava in The Pharmacogenomics Journal (2022)

  6. Article

    Open Access

    CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method

    Berzosertib (M6620) is a highly potent (IC50  =  19 nM) and selective, first-in-class ataxia telangiectasia-mutated and Rad3-related protein kinase (ATR) inhibitor. This trial assessed the safety, preliminary ...

    S. R. Javed, S. Lord, S. El Badri, R. Harman, J. Holmes in British Journal of Cancer (2024)